CCL21 Cancer Immunotherapy

Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yuan, Sharma, Sherven, John, Maie St.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074818/
https://www.ncbi.nlm.nih.gov/pubmed/24810425
http://dx.doi.org/10.3390/cancers6021098
_version_ 1782323252309262336
author Lin, Yuan
Sharma, Sherven
John, Maie St.
author_facet Lin, Yuan
Sharma, Sherven
John, Maie St.
author_sort Lin, Yuan
collection PubMed
description Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.
format Online
Article
Text
id pubmed-4074818
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40748182014-06-30 CCL21 Cancer Immunotherapy Lin, Yuan Sharma, Sherven John, Maie St. Cancers (Basel) Review Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer. MDPI 2014-05-07 /pmc/articles/PMC4074818/ /pubmed/24810425 http://dx.doi.org/10.3390/cancers6021098 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Lin, Yuan
Sharma, Sherven
John, Maie St.
CCL21 Cancer Immunotherapy
title CCL21 Cancer Immunotherapy
title_full CCL21 Cancer Immunotherapy
title_fullStr CCL21 Cancer Immunotherapy
title_full_unstemmed CCL21 Cancer Immunotherapy
title_short CCL21 Cancer Immunotherapy
title_sort ccl21 cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074818/
https://www.ncbi.nlm.nih.gov/pubmed/24810425
http://dx.doi.org/10.3390/cancers6021098
work_keys_str_mv AT linyuan ccl21cancerimmunotherapy
AT sharmasherven ccl21cancerimmunotherapy
AT johnmaiest ccl21cancerimmunotherapy

Ejemplares similares